Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to -$1.2 million.

  • Coya Therapeutics' Change in Accured Expenses fell 39557.52% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229472.0, marking a year-over-year decrease of 299.67%. This contributed to the annual value of -$1.5 million for FY2024, which is 27065.64% down from last year.
  • Latest data reveals that Coya Therapeutics reported Change in Accured Expenses of -$1.2 million as of Q3 2025, which was down 39557.52% from $1.0 million recorded in Q2 2025.
  • Coya Therapeutics' 5-year Change in Accured Expenses high stood at $1.7 million for Q4 2023, and its period low was -$1.3 million during Q1 2023.
  • Over the past 4 years, Coya Therapeutics' median Change in Accured Expenses value was $166153.0 (recorded in 2022), while the average stood at $30460.0.
  • The largest annual percentage gain for Coya Therapeutics' Change in Accured Expenses in the last 5 years was 156772.29% (2023), contrasted with its biggest fall of 87539.91% (2023).
  • Quarter analysis of 4 years shows Coya Therapeutics' Change in Accured Expenses stood at $102751.0 in 2022, then skyrocketed by 1567.72% to $1.7 million in 2023, then plummeted by 101.24% to -$21174.0 in 2024, then plummeted by 5567.23% to -$1.2 million in 2025.
  • Its Change in Accured Expenses stands at -$1.2 million for Q3 2025, versus $1.0 million for Q2 2025 and $421523.0 for Q1 2025.